Viatris CEO Says Met With FDA In November On Indore Facility Progress, Will Be Ready For Reinspection This Year But Timing Up To FDA; Exec Says About 50% Of $650M Savings Coming From Job Cuts; Assumes Little Less Than 1% Of Indore Recovery Baked Into Top Line Forecast; Indore Would Not Have Material Impact On 2026 Forecast; Has Requalified Other Plants And Found Alternate Sources For Indore Plant